Galapagos/GLPG

-1.25%
-
1D1W1MYTD1YMAX

About Galapagos

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. It discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The Company acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.

Ticker

GLPG

Sector

Healthcare

Trading on

AEX

Industry

Biotechnology & Drugs

CEO

Paulus Stoffels

Employees

646

Headquarters

Malines (mechelen), Belgium

Galapagos Metrics

BasicAdvanced
€1.88B
Market cap
8.87
P/E ratio
€3.21
EPS
-0.01
Beta
-
Dividend rate
€1.88B
-0.01242
€41.92
€28.44
79.85K
9.018
8.845
0.177
0.343
-0.09%
-0.15%
-0.1%
8.87
6.544
0.672
0.723
3.47%
94.43%
-18.51%

What the Analysts think about Galapagos

Analyst Ratings

Majority rating from 12 analysts.
Hold

Price Targets

Average projection from 11 analysts.
45.54% upside
High €55.00
Low €33.00
€28.50
Current price
€41.48
Average price target

Galapagos Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
73.75% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
€286.9M
110.49%
Net income
€211.6M
720.16%
Profit margin
73.75%
289.8%

Galapagos Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 160.83%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Actual
€0.08
€0.39
€2.39
-
Expected
-€0.83
-€0.96
-€3.93
-€0.14
Surprise
-109.58%
-140.63%
-160.83%
-
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by ICE Data Services and Euronext. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Galapagos stock?

Galapagos (GLPG) has a market cap of €1.88B as of April 13, 2024.

What is the P/E ratio for Galapagos stock?

The price to earnings (P/E) ratio for Galapagos (GLPG) stock is 8.87 as of April 13, 2024.

Does Galapagos stock pay dividends?

No, Galapagos (GLPG) stock does not pay dividends to its shareholders as of April 13, 2024.

When is the next Galapagos dividend payment date?

Galapagos (GLPG) stock does not pay dividends to its shareholders.

What is the beta indicator for Galapagos?

Galapagos (GLPG) has a beta rating of -0.01. This means that it has an inverse relation to market volatility.

What is the Galapagos stock price target?

The target price for Galapagos (GLPG) stock is €41.48, which is 45.54% above the current price of €28.5. This is an average based on projections from 11 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Galapagos stock

Buy or sell Galapagos stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing